Pharmaceutical company Definium Therapeutics has completed another phase of clinical trials for a drug based on lysergic acid (LSD). The new fast-dissolving tablet demonstrated strong results in treating generalized anxiety disorder, infohub.kz reports.
According to the company, a single 100-microgram dose of DT120 — a fast-dissolving lysergide (LSD) tablet — reduced anxiety scores by 9.8 points at 12 weeks. By comparison, the placebo group saw a 4.7-point reduction.
Earlier, in August, Definium Therapeutics had already reported that in the first DT120 study the drug also significantly reduced anxiety symptoms in generalized anxiety disorder.
CEO Robert Barrow said Definium plans to file for approval with the U.S. Food and Drug Administration (FDA) in the first half of 2027.
Before that, in June of this year, the company reported that the drug was also successfully used to treat depression in another late-stage study. Definium is reportedly seeking to expand indications for the treatment of both generalized anxiety disorder and depression.
"It's striking to see three consecutive studies that demonstrate consistent results — you don't usually see that in neuropsychology," said Evercore ISI analyst Gavin Clark-Gartner.
Generalized anxiety disorder (GAD) affects about 3% of people worldwide each year — hundreds of millions of people. It is typically treated with antidepressants, anti-anxiety medications, and psychotherapy. Notably, in nearly two decades, no new treatment has been approved.
Earlier, Kursiv wrote that American scientists found the reason why it is so hard for people to escape depressive states.